WallStSmart

Chemed Corp (CHE)vsDaVita HealthCare Partners Inc (DVA)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

DaVita HealthCare Partners Inc generates 439% more annual revenue ($13.64B vs $2.53B). CHE leads profitability with a 10.5% profit margin vs 5.5%. DVA appears more attractively valued with a PEG of 0.56. DVA earns a higher WallStSmart Score of 66/100 (B-).

CHE

Buy

51

out of 100

Grade: C-

Growth: 3.3Profit: 8.0Value: 7.3Quality: 7.0
Piotroski: 3/9Altman Z: 5.81

DVA

Strong Buy

66

out of 100

Grade: B-

Growth: 6.0Profit: 7.0Value: 8.7Quality: 4.3
Piotroski: 3/9Altman Z: 1.22
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

CHESignificantly Overvalued (-270.8%)

Margin of Safety

-270.8%

Fair Value

$124.85

Current Price

$374.02

$249.17 premium

UndervaluedFair: $124.85Overvalued
DVAUndervalued (+11.7%)

Margin of Safety

+11.7%

Fair Value

$163.40

Current Price

$155.11

$8.29 discount

UndervaluedFair: $163.40Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CHE3 strengths · Avg: 9.3/10
Altman Z-ScoreHealth
5.8110/10

Safe zone — low bankruptcy risk

Return on EquityProfitability
25.3%9/10

Every $100 of equity generates 25 in profit

Debt/EquityHealth
0.139/10

Conservative balance sheet, low leverage

DVA3 strengths · Avg: 8.7/10
Return on EquityProfitability
64.8%10/10

Every $100 of equity generates 65 in profit

PEG RatioValuation
0.568/10

Growing faster than its price suggests

P/E RatioValuation
16.1x8/10

Attractively priced relative to earnings

Areas to Watch

CHE4 concerns · Avg: 2.8/10
PEG RatioValuation
1.604/10

Expensive relative to growth rate

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Revenue GrowthGrowth
-0.1%2/10

Revenue declined 0.1%

EPS GrowthGrowth
-9.1%2/10

Earnings declined 9.1%

DVA3 concerns · Avg: 2.7/10
Profit MarginProfitability
5.5%3/10

5.5% margin — thin

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Altman Z-ScoreHealth
1.222/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : CHE

The strongest argument for CHE centers on Altman Z-Score, Return on Equity, Debt/Equity.

Bull Case : DVA

The strongest argument for DVA centers on Return on Equity, PEG Ratio, P/E Ratio. PEG of 0.56 suggests the stock is reasonably priced for its growth.

Bear Case : CHE

The primary concerns for CHE are PEG Ratio, Piotroski F-Score, Revenue Growth.

Bear Case : DVA

The primary concerns for DVA are Profit Margin, Piotroski F-Score, Altman Z-Score.

Key Dynamics to Monitor

CHE profiles as a declining stock while DVA is a value play — different risk/reward profiles.

DVA carries more volatility with a beta of 0.93 — expect wider price swings.

DVA is growing revenue faster at 9.9% — sustainability is the question.

DVA generates stronger free cash flow (395M), providing more financial flexibility.

Bottom Line

DVA scores higher overall (66/100 vs 51/100). Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Chemed Corp

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Chemed Corporation provides hospice and hospice services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers across the United States. The company is headquartered in Cincinnati, Ohio.

Visit Website →

DaVita HealthCare Partners Inc

HEALTHCARE · MEDICAL CARE FACILITIES · USA

DaVita Inc. provides kidney dialysis services through a network of outpatient dialysis centers in the United States.

Want to dig deeper into these stocks?